In univariate analyses (Table 3), having seen more than one doctor pre-study, having a treatment decision at study entry, reporting more knowledge, and baseline hormonal symptoms were associated with lower DC related to support needed to make a decision.
The RCOG list doesn't even have that to its credit because, for many of the substances it lists, pre-clinical studies have simply hinted that they might be harmful.
The promising results of pre-clinical studies have lead to the first early phase clinical trials.
Pre-clinical studies have shown a slow rate of internalization of GPC3 targeted with antibody [17, 18].
Abundant pre-clinical studies have documented in the anti-diabetic and hypoglycaemic effects of M. charantia through various postulated mechanisms.
Such pre-injection studies have generally not been done in the past, although some new state regulations are moving in that direction.
Pre-clinical studies have raised hope in functional recovery through the antagonism of growth inhibitors, application of growth factors, cell transplantation, and vaccination strategies.
Some pre-clinical studies have also compared DWI changes with thermal dose estimates during prostate treatments [24, 25] but the relationship between ADC and thermal dose has not been previously described in bony regions.
Previous pre-clinical studies have shown a potential of MUT for breast lesion detection and characterisation [15, 16, 17], but an evaluation of the system in a full clinical setting was lacking.
Although pre-clinical studies have shown promising results, further studies are required to explore the in-depth molecular mechanisms responsible for the observed pharmacological activities and to test the efficacy of isolated compounds or standardised extracts in properly designed experiments.
